The Single Best Strategy To Use For Temazepam
The Single Best Strategy To Use For Temazepam
Blog Article
nirmatrelvir will improve the stage or impact of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
You should not use this medication if you are allergic to doxepin, amoxapine, or loxapine, or if you have:
For oral prescription drugs the place reductions in bioavailability might cause clinically substantial outcomes on its security or efficacy, independent administration of ferric maltol from these medication. Length of separation could rely upon the absorption with the medication concomitantly administered (eg, the perfect time to peak focus, whether the drug is an immediate or extended release item).
Exceptions to this monograph are talked over in further more detail in different drug conversation monographs. Look at therapy modification
Coadministration of pexidartinib (a CYP3A4 inducer) with delicate CYP3A substrates might cause serious therapeutic failures. If concomitant use is unavoidable, raise the CYP3A substrate dosage in accordance with permitted product labeling.
Limit dosages and durations on the least required. Follow sufferers for signals and symptoms of respiratory melancholy and sedation.
mitotane decreases levels of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Mitotane is a strong inducer of cytochrome P-4503A4; keep an eye on when coadministered with CYP3A4 substrates for achievable dosage changes.
armodafinil will lower the extent or effect of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
teclistamab will boost the degree or impact of triazolam by altering metabolism. Use Caution/Keep track of. Teclistamab leads to release of cytokines that may suppress exercise of CYP450 enzymes, causing amplified exposure of CYP substrates.
lapatinib will enhance the degree or influence Estazolam of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
If concomitant use is unavoidable, improve CYP3A substrate dosage in accordance with approved products labeling.
prednisone will decrease the extent or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Coadministration with CYP3A4 substrates, especially All those having a slim therapeutic index, may result in reduced concentrations and loss of efficacy. If not able to avoid coadministration, observe CYP3A4 substrate ranges and change dose as desired.
indinavir will boost the amount or influence of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.